The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors

British Journal of Pharmacology

Volumn 167, Issue 6, 2012, Pages 1329-1341

  Olianas, Maria C ^a   Dedoni, Simona ^a   Onali, Pierluigi ^a  

^a Cittadella Universitaria di Monserrato   (Italy)

Author keywords

35S GTPI S binding assay; atypical antidepressants; CHO cells; cloned and native opioid receptor; MAPK phosphorylation; mouse primary neurons; radioligand binding assays; rat C6 glioma cells

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; DYNORPHIN A; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MIANSERIN; MIRTAZAPINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MU OPIATE RECEPTOR; NORBINALTORPHIMINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN MEMBRANE; BRAIN REGION; CELLULAR DISTRIBUTION; CHO CELL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; GENETIC TRANSFECTION; GLIOMA CELL; LIGAND BINDING; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RADIOASSAY; RAT; RECEPTOR BLOCKING; TISSUE DISTRIBUTION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BASAL GANGLIA; CELL LINE, TUMOR; CELLS, CULTURED; CHO CELLS; CREB-BINDING PROTEIN; CRICETINAE; CRICETULUS; FEMALE; HUMANS; MALE; MIANSERIN; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; RECOMBINANT PROTEINS;

EID: 84867807501     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02078.x     Document Type: Article

References (61)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Altamura AC, De Novellis F, Mauri MC, Gomeni R, (1987). Plasma and brain pharmacokinetics of mianserin after single and multiple dosing in mice. Prog Neuropsychopharmacol Biol Psychiatry 11: 23-33.
3. Baldessarini RJ, (2006). Drug therapy of depression and anxiety disorders. In:, Brunton LL, Lazo JS, Parker KL, (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. McGraw-Hill Book Companies: New York, NY, pp. 429-459.
4. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS, (1993). Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place-preference paradigm in rats. J Pharmacol Exp Ther 264: 489-495.
5. Benbouzid M, Choucair-Jaafar N, Yalem I, Waltisperger E, Muller A, Freund-Mercier MJ, et al,. (2008a). Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice. Eur J Pain 12: 1008-1017.
6. Benbouzid M, Gaveriaux-Ruff C, Yalcin I, Waltisperger E, Tessier L-H, Muller A, et al,. (2008b). Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. Biol Psychiatry 63: 633-636.
7. Besson A, Privat AM, Eschalier A, Fialip J, (1999). Dopaminergic and opioidergic mediations of tricyclic antidepressants in the learned helplessness paradigm. Pharmacol Biochem Behav 64: 541-548.
8. Biegon A, Samuel D, (1980). Interaction of tricyclic antidepressants with opiate receptors. Biochem Pharmacol 29: 460-462.
9. Bilkei-Gorzo A, Racz I, Michel K, Mauer D, Zimmer A, Klingmuller D, et al,. (2008). Control of hormonal stress reactivity by the endogenous opioid system. Psychoneuroendocrinology 33: 425-436.
10. Blendy JA, (2006). The role of CREB in depression and antidepressant treatment. Biol Psychiatry 59: 1144-1150.
11. Bohn LM, Belcheva MM, Coscia CJ, (2000). Mitogenic signaling via endogenous κ-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade. J Neurochem 74: 564-573.
12. Bradford MM, (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
13. Bruchas MR, Macey TA, Lowe JD, Chavkin C, (2006). Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem 281: 18081-18089.
14. Bruchas MR, Land BB, Aita M, Xu M, Barot SK, Li S, et al,. (2007). Stress-induced p38 mitogen-activated protein kinase activation mediates κ-opioid-dependent dysphoria. J Neurosci 27: 11614-11623.
15. Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Land BB, et al,. (2011). Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 11: 383-385.
16. Bruijnzeel AW, (2009). kappa-Opioid receptor signaling and brain reward function. Brain Res Rev 62: 127-146.
17. Carlezon WA Jr, Beguin C, Knoll AT, Cohen BM, (2009). Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther 123: 334-343.
18. Croom KF, Perry CM, Plosker GL, (2009). Mirtazapine. A review of its use in major depression and other psychiatric disorders. CNS Drugs 23: 427-452.
19. Devoize JL, Rigal F, Eschalier A, Trolese JF, (1982). Naloxone inhibits clomipramine in mouse forced swimming test. Eur J Pharmacol 78: 229-231.
20. Doxey JC, Everitt J, Metcalf G, (1978). Mianserin- An analysis of its peripheral autonomic actions. Eur J Pharmacol 51: 1-10.
21. Duman CH, Schlesinger L, Kodama M, Russell DS, Duman RS, (2007). A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 61: 661-670.
22. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, et al,. (2000). Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25: 195-200.
23. Gray AM, Spencer PSJ, Sewell RDE, (1998). The involvement of the opioidergic system in the antinociceptive mechanisms of action of antidepressant compounds. Br J Pharmacol 124: 669-674.
24. Ho BY, Takemori AE, (1989). Serotonergic involvement in the antinociceptive action of and the development of tolerance to the kappa-opioid receptor agonist, U-50,488H. J Pharmacol Exp Ther 250: 508-514.
25. Isenberg KE, Cicero TJ, (1984). Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds. Eur J Pharmacol 103: 57-63.
26. Kudryavtseva NN, Gerrits MAFM, Avgustinovich DF, Tenditnik MV, Van Ree JM, (2004). Modulation of anxiety-related behaviors by μ- and κ-opioid receptor agonists depends on the social status of mice. Peptides 25: 1355-1363.
27. Kurata K, Kurachi M, (1989). Heterogeneous distribution of mianserin in rat brain during chronic continuous infusion. Pharmacology 39: 285-290.
28. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C, (2008). The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 28: 407-414.
29. Lonze BE, Ginty DD, (2002). Function and regulation of CREB family transcription factors in the nervous system. Neuron 35: 605-623.
30. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
31. McLaughlin JP, Marton-Popovici M, Chavkin C, (2003). Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23: 5674-5683.
32. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, et al,. (2003). Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305: 323-330.
33. Mansour A, Fox CA, Akil H, Watson SJ, (1995). Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18: 22-29.
34. Marchand F, Ardid D, Chapuy E, Alloui A, Jourdan D, Eschalier A, (2003). Evidence for an involvement of supraspinal δ- and spinal μ-opioid receptors in the antihyperalgesic effect of chronically administered clomipramine in mononeuropathic rats. J Pharmacol Exp Ther 307: 268-274.
35. Marshall RJ, (1983). The pharmacology of mianserin-An update. Br J Clin Pharmacol 15: 263S-268S.
36. Metcalf MD, Coop A, (2005). Kappa-opioid antagonists: past successes and future prospects. AAPS J 7: E704-E722.
37. Mico JA, Ardid D, Berrocoso E, Eschalier A, (2006). Antidepressants and pain. Trends Pharmacol Sci 27: 348-354.
38. Narita M, Kaneko C, Miyoshi K, Nagumo Y, Kuzumaki N, Nakajima M, et al,. (2006). Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala. Neuropsychopharmacology 31: 739-750.
39. Olianas MC, Concas D, Onali P, (2006). Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors. Br J Pharmacol 147: 360-370.
40. st Neuropharmacology Conference. Abstr. p.37.
41. 1-like receptor signalling in rat nucleus accumbens. Eur J Pharmacol 448: 105-111.
42. Onali P, Dedoni S, Olianas MC, (2010). Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. J Pharmacol Exp Ther 332: 255-265.
43. Otani K, Sasa H, Kaneko S, Kondo T, Fukushima Y, (1993). Steady-state plasma concentrations of mianserin and its major active metabolita, desmethylmianserin. Ther Drug Monit 15: 113-117.
44. Ozturk Y, Aydin S, Beis R, Herekman-Demir T, (2006). The involvement of endogenous opioid mechanisms in the antinociceptive effects induced by antidepressant drugs, desipramine and trimipramine. Pharmacol Biochem Behav 83: 592-597.
45. 1 receptors in rat brain. J Pharmacol Exp Ther 216: 142-148.
46. Pfeiffer A, Brantl V, Herz A, Emrich HM, (1986). Psychotomimesis mediated by kappa opiate receptors. Science 233: 774-776.
47. Pinder RM, (1985). Adrenoreceptor interactions of the enantiomers and metabolites of mianserin: are they responsible for the antidepressant effect ? Acta Psychiatr Scand 72 (Suppl. 320): 1-9.
48. Privette TH, Terrian DM, (1995). Kappa opioid agonists produce anxiolytic-like behaviour on the elevated plus-maze. Psychopharmacology 118: 444-450.
49. Raiteri M, Maura G, Gemignani A, Pittaluga A, (1983). Differential blockade by (-)mianserin of the alpha2-adrenoceptors mediating inhibition of noradrenaline and serotonin release from rat brain synaptosomes. Naunyn Schmiedebergs Arch Pharmacol 322: 180-182.
50. Reichenberg K, Gaillard-Plaza G, Montastruc JL, (1985). Influence of naloxone on the antinociceptive effects of some antidepressant drugs. Arch Int Pharmacodyn Ther 275: 78-85.
51. Richelson E, Nelson A, (1984). Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230: 94-102.
52. Rose A, McCulloch MW, Sarantos-Laska C, Rand MJ, (1984). Effects of mianserin on noradrenergic mechanisms. J Psychiatr Res 18: 79-88.
53. Schoemaker H, Berendsen HHG, Stevens HJT, Nickolson VJ, (1981). Differences in presynaptic α-blockade, noradrenaline uptake inhibition, and potential antidepressant activity between (+)- and (-)mianserin. Psychopharmacology 74: 137-142.
54. Schreiber S, Backer MM, Kaufman JP, Pick CG, (1998). Interaction between the tetracyclic antidepressant mianserin HCl and opioid receptors. Eur Neuropsychopharmacol 8: 297-302.
55. Schreiber S, Rigai T, Katz Y, Pick CG, (2002). The antinociceptive effect of mirtazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanisms. Brain Res Bull 28: 601-605.
56. Tegeder I, Geisslinger G, (2004). Opioids as modulators of cell death and survival- Unraveling mechanisms and revealing new indications. Pharmacol Rev 56: 351-369.
57. Tejedor-Real P, Mico JA, Maldonado R, Roques BP, Gibert-Rahola J, (1995). Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol Biochem Behav 52: 145-152.
58. Tokimasa T, Ariyoshi M, Akasu T, (1987). Mianserin blocks α2 adrenoceptors in submucous neurones of the guinea-pig caecum. Eur J Pharmacol 143: 243-250.
59. Wall PM, Messier C, (2000). U-69,593 microinjection in the infralimbic cortex reduces anxiety and enhances spontaneous alternation memory in mice. Brain Res 856: 259-280.
60. Wittmann W, Schunk E, Rosskothen I, Gaburro S, Singewald N, Herzog H, et al,. (2009). Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology 34: 775-785.
61. Zhao Z-Q, Gao Y-J, Sun Y-G, Zhao C-S, Gereau IVRW, Chen Z-F, (2007). Central serotonergic neurons are differentially required for opioid analgesia but not for morphine tolerance or morphine reward. Proc Natl Acad Sci USA 104: 14519-14524.